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Abstract
Objective To estimate the potential cost effectiveness of a
population-wide risk factor reduction programme aimed at preventing
cardiovascular disease.
Design Economic modelling analysis.
Setting England and Wales.
Population Entire population.
Model Spreadsheet model to quantify the reduction in cardiovascular
disease over a decade, assuming the benefits apply consistently for
men and women across age and risk groups.
Main outcome measures Cardiovascular events avoided, quality
adjusted life years gained, and savings in healthcare costs for a given
effectiveness; estimates of how much it would be worth spending to
achieve a specific outcome.
Results A programme across the entire population of England and
Wales (about 50 million people) that reduced cardiovascular events by
just 1% would result in savings to the health service worth at least £30m
(€34m; $48m) a year compared with no additional intervention. Reducing
mean cholesterol concentrations or blood pressure levels in the
population by 5% (as already achieved by similar interventions in some
other countries) would result in annual savings worth at least £80m to
£100m. Legislation or other measures to reduce dietary salt intake by
3 g/day (current mean intake approximately 8.5 g/day) would prevent
approximately 30 000 cardiovascular events, with savings worth at least
£40m a year. Legislation to reduce intake of industrial trans fatty acid
by approximately 0.5% of total energy content might gain around 570
000 life years and generate NHS savings worth at least £230m a year.
Conclusions Any intervention that achieved even a modest
population-wide reduction in any major cardiovascular risk factor would
produce a net cost saving to the NHS, as well as improving health. Given
the conservative assumptions used in this model, the true benefits would
probably be greater.
Introduction
Cardiovascular diseases (principally coronary heart disease and
stroke) together account for more than 150 000 deaths a year
in the United Kingdom.1 Cardiovascular diseases affect more
than five million people, and annual costs exceed £30bn (€34bn;
$48bn).2 However, more than 80% of premature (at age <75)
cardiovascular disease is avoidable.3 4
The UK government strategy for the primary prevention of
cardiovascular disease therefore focuses on a dual approach.
National Health Service (NHS) health checks to detect and treat
people at high risk are underpinned by policies benefiting the
entire population, such as smoke-free legislation and the
progressive reduction in the salt content of processed food.5 6
In 2004 the Wanless report suggested that a more “fully
engaged” population-wide prevention strategymight save £36bn
a year.7 Abelson estimated comparable savings in Australia.8
More recently, the Trust for America’s Health calculated a six
for one return on investment for population-wide approaches
to prevention in the United States.9
Elsewhere, many studies have suggested that tobacco control
programmes are cost saving.10 Likewise, dietary salt reduction
policies consistently seem to be very cost effective,11 or even
cost saving.12 13 However, data on the economics of other
population based dietary interventions, such as the eradication
of trans fats or reduction of saturated fat, are much scarcer.10-15
The effectiveness and cost effectiveness of population based
dietary approaches to prevention of cardiovascular disease in
the UK are less clear. The Department of Health therefore asked
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the National Institute for Health and Clinical Excellence to
develop guidance on a public health programme aimed at
preventing cardiovascular disease in whole populations. To
inform this programme, we built a generic economic model to
estimate the comparative cost effectiveness of such
interventions. After initial development and testing, we applied
this model to two general scenarios involving small decreases
in population levels of blood pressure or total cholesterol
concentrations and to two specific legislative interventions
aimed at reducing the dietary intake of salt and trans fats.
Methods
After consultation with stakeholders, we built a generic
spreadsheet model quantifying a range of possible interventions,
which could estimate cases of cardiovascular disease and deaths
due to cardiovascular disease prevented or postponed, life years
and quality adjusted life years (QALYs) gained, and cost savings
to the NHS resulting from cases prevented or postponed. After
initial development and testing, we applied this model to two
general scenarios involving small decreases in blood pressure
and total cholesterol concentration and to two specific examples
of legislative interventions to reduce the dietary intakes of salt
and trans fats.
Model development
We developed a spreadsheet model in four successive stages:
costs, cases prevented, individual benefits, then aggregating the
benefits.
Determining NHS costs and QALYs lost for one
case of cardiovascular disease
For costing, we adapted the principles of the Sheffield
prevention model, updating unit costs and otherwise inflating
to 2008.16 These are detailed in the web appendix. All new costs
and inflation indices came from Curtis.17
We estimated the expected lifetime costs, life years, and QALYs
after a first cardiovascular event as a function of age and sex.
Comparing these with life expectancy without an event then
gave the loss in life years and QALYs from such an event. For
example, we considered the case of a 65 year old man who
developed stable angina. We combined life expectancy data
from the government actuary’s department with quality of life
data from Sheffield to estimate a discounted quality adjusted
life expectancy of 8.50 QALYs.16 We used data from Ward et
al to estimate lifetime treatment costs with stable angina of
£2338 and a loss of 2.12 QALYs.16 We then did similar
calculations for a 65 year old man having a first cardiovascular
event to estimate lifetime treatment costs and QALYs lost. The
range of cardiovascular events reflected the typical age
dependent case mix.16 We then repeated this process for men
and women at all ages from 40 to 90 years (see appendix).
Assessing pattern of cases of cardiovascular
disease prevented or postponed for intervention
of known effectiveness, using Framingham risk
equation applied to single birth cohort
We assessed the pattern of cases prevented or postponed by an
intervention of known effectiveness. We used the Framingham
risk equations to generate the expected pattern of first
cardiovascular events according to the person’s age, sex, and
risk of cardiovascular disease.18
To estimate the effect of an intervention, we used a relative risk
applied to the annual risk of a first cardiovascular event. This
generated expected reductions in first cardiovascular events
over a 10 year period. The appendix shows an example for a 65
year old man with a 10 year risk of cardiovascular disease of
12.5% and an intervention achieving an annual relative risk of
0.9. We then did similar calculations for all men and women in
10 year age bands from 45 to 75. The distribution of risk factors
in 10 year age groups was based on the Joint British Societies’
guidelines.19 For ease of modelling, we took the “under 10%”
cardiovascular disease risk group at 7.5% and the “over 30%”
risk group at 32.5%.
Combining results from first two stages to
estimate potential outcomes for single
combination of age, sex, and risk
We then combined the results of the first two stages to produce
estimates of deaths prevented, life years gained, QALYs gained,
and cost savings separately for each group. The appendix shows
an illustrative example for an intervention with relative risk 0.9
applied to 65 year old men.
Generating output for men and women of all
ages, then aggregating results to give total
estimated NHS costs and QALYs gained at level
of entire England and Wales population of 50
million
To reflect the nature of the risk equation and the assumptions
needed, we conservatively estimated benefits from a reduction
in the number of cases over a 10 year time horizon. We then
expressed the output on an annual basis. We then aggregated
the results across these distributions to give us expected
outcomes for men and women of unknown cardiovascular
disease risk in 10 year age bands.
We calculated the total population effects for 10 year age groups
in England andWales by using data from the Office for National
Statistics.20 We then calculated the total population without
cardiovascular disease eligible for primary prevention by
subtracting the Sheffield estimate of the people with a history
of cardiovascular disease from the population total.16 Scaling
up the group results then provided the estimates for the total
population (see appendix).
We used NICE’s standard annual discount rate of 3.5% for both
costs and outcomes.We have converted total savings into annual
equivalent savings across each of the 10 years, after allowing
for the discounting applied. Full technical details of the model
are available in the appendix and on the NICE website.21
Results
Generic population-wide interventions
Reducing the cardiovascular risk of the population by just 1%
sustained over 10 years would prevent approximately 25 000
new cases of cardiovascular disease and 3500 deaths from
cardiovascular disease. This would gain around 98 000 QALYs
and would generate total (discounted) savings of approximately
£265m, equivalent to annual savings across the 10 years of the
programme of approximately £30m, compared with no
additional intervention (table 1). Here, and elsewhere, a large
part of the substantial gain in QALYs is due to the prevention
of non-fatal events that strongly affect quality of life. The
number of QALYs gained therefore exceeds the number of life
years gained.
Reducing population blood pressure levels or total cholesterol
concentrations by 5% would result in correspondingly larger
health gains. Annual equivalent savings would be approximately
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£100 million for blood pressure (table 2) and £80 million for
cholesterol (table 3).
Specific interventions
Legislation to reduce salt intake
Dietary salt intake in England andWales averages approximately
8.5 g/day. A reduction of 3 g/day in salt intake represents a
conservative estimate of the potential effects of specific
legislation, based on the 6 g reduction achieved in Finland,
Japan, and elsewhere.22 Reducing salt intake by 3 g/day might
reduce mean population systolic blood pressure by
approximately 2.5mmHg.23This would equate to a 2% decrease
in the risk reduction model.23 This would prevent approximately
4450 deaths from cardiovascular disease, with total discounted
savings overall of approximately £347m over a decade,
representing equivalent annual savings of approximately £40m
(table 4). Any salt reduction intervention totalling up to £40m
a year would therefore still be cost saving.
Legislation to ban industrial fats
Industrial trans fats account for approximately 0.8% of total
UK dietary energy intake.23 Based on experience in Denmark,
trans fat levels could be reduced by approximately 0.5% of total
UK dietary energy intake.15 24 This would reduce the relative
risk of death from cardiovascular disease by approximately
6%.25 Applying these benefits to the entire England and Wales
population would prevent approximately 2700 deaths annually
and thus gain 570 000 life years, saving the equivalent of
approximately £235m a year (table 5). An intervention costing
up to £230m a year would therefore still be cost saving if it
achieved the desired reduction in trans fats.
Sensitivity analyses
We did an extensive series of sensitivity analyses. In brief,
savings occurred even when the background risk was reduced
by 5% or 50%. Corresponding increases of 5% and 50% are
also shown for completeness in the web appendix.
Discussion
Our results strongly suggest that any policy intervention
achieving even a 1% population-wide reduction in risk of
cardiovascular disease can be expected to produce a net cost
saving to the NHS, as well as decreasing losses in productivity
and improving health. Only if a very large sum of money needs
to be spent on implementing the legislation would this cease to
be the case. Our findings are reassuringly consistent with
analyses from the United States, Australia, and the UK
Treasury.7-15 26 Likewise, a five year campaign on salt reduction
by the UK Food Standards Agency cost approximately £15m
and achieved a reduction of 0.9 g/day in average salt intake.
This was estimated to prevent approximately 6000
cardiovascular deaths a year, with estimated savings totalling
some £1.5bn, or £300m a year.6 Furthermore, analyses of cohorts
with lower cardiovascular risk show fewer cardiovascular events
delayed to an older age and incurring substantially lower
Medicare costs.27
The 5% reductions modelled for systolic blood pressure and
cholesterol concentration are entirely consistent with the actual
falls achieved in regional programmes such as North Karelia,
Stanford, and HeartBeat Wales.28 29 Furthermore, much larger
reductions in entire populations have been documented since
the 1980s. For instance, cholesterol reductions of 22% in
Finland, 14% in Iceland, 10% in Sweden, and 6% in the United
States have been reported.30 31 32 33 Likewise, blood pressure
reductions of 8% in England and 6% in Finland have been
reported.29 30
Our 0.5% reduction in industrial trans fats represents a
conservative estimate of what is possible, given past UK trends
and recent Danish experience of successful eradication.34
Industrial trans fats have now been banned in five European
countries: Denmark, Switzerland, Austria, Sweden, and Iceland.
Manufacturers have adapted rapidly, easily, and with minimal
costs.35 We would suggest that the UK is unlikely to be very
different. Furthermore, important inequalities exist, given the
very high consumption of trans fats recently reported in some
disadvantaged groups (exceeding 6% of daily energy).35Benefits
in deprived communities might therefore be even larger.
Strengths of analysis
Our spreadsheet model allows a relative risk to be applied to
each year’s risk of primary cardiovascular disease in the
population. It also allows percentage reductions in cholesterol
concentration and systolic blood pressure to be considered
separately for men and women. The model is designed to be
transparent and involves relatively few assumptions, each of
which can be easily tested. Furthermore, the estimates are based
on a series of conservative assumptions, so the true benefits are
likely to be substantially larger.
We quantified only NHS savings. Net social savings will clearly
be much larger. The model focuses on primary prevention of
cardiovascular disease. All population-wide risk factor reduction
programmes considered in this report would also benefit the
five million patients with recognised cardiovascular disease in
the UK.36 37 Substantial reductions in diabetes, many common
cancers, and other chronic diseases would also occur.37
This simple model assumed a uniform distribution of burden
and benefit across social groups. In fact, deprived groups have
disproportionately more disease and would thus gain more from
population-wide risk factor reductions. Absolute inequalities
would also be decreased.38
This is not simply a cost of illness study. It is a modelling study
that shows the range of possible cost savings andQALY benefits
from a range of plausible interventions. It therefore allows an
upper limit to be placed on the cost at which any such
intervention would be worthwhile. Greater complexity in the
model might lead to additional precision in the results. However,
we suggest that this additional precisionmight make surprisingly
little difference to the key policy decisions.
The sensitivity analyses were reassuring and suggested that
using a different risk “engine” to drive the model would have
a relatively modest effect. The model is based on the original
Framingham equations and the same risk score as the Joint
British Societies’ guidelines, which is widely used and
understood. It also reflects the model that was presented to the
NICE Programme Development Group to assist in their
deliberations and inform their subsequent key
recommendations.35
Limitations of analysis
Our conclusions are clearly subject to several important
limitations reflecting the nature of the model. Apart from the
increased mortality immediately after a first non-fatal primary
cardiovascular event, we made no attempt to consider recurrent
events or subsequent deaths. The estimates of deaths avoided,
life years gained, and cost savings are thus likely to be
underestimates, making the analysis somewhat conservative. A
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further limitation is the 10 year time frame for prevention of
cases; gains over a lifetime would clearly be greater.
The analysis was pragmatically limited to people aged between
40 and 79 years at the time of the intervention. However, given
the very high rates of cardiovascular events in people aged over
80, substantial additional benefits might be expected. Our
interventions assumed relatively uniform effects across age and
risk groups by definition. However, the subsequent changes in
specific risk factors included age gradients and considered men
and women separately.
In this study, the counterfactual (no intervention) implicitly
assumes that the population risk of cardiovascular disease would
remain constant. However, there may be a “natural” increase
or decrease in cardiovascular risk without population-wide
interventions. Modest changes could also follow targeted
interventions in subgroups. Either of these scenarios might affect
future costs and QALYs.
Finally, this initial modelling lacks a full probabilistic sensitivity
analysis, because many essential data inputs (such as the
distribution of risk factors in the population) were readily
available only as point estimates. However, the range of changes
in risk factors and their effects quantified in the results tables
and web appendices provide a satisfactory and rigorous
sensitivity analysis. Future studies might usefully include a full
probabilistic sensitivity analysis to formally test the uncertainties
inherent in the various modelling assumptions.
Implications of findings
We estimated that a 1% reduction in the relative risk of
cardiovascular disease would generate discounted NHS savings
of approximately £30m a year in England andWales, compared
with no additional intervention, This estimate is considerably
less than 1% of the £7bn healthcare costs calculated by
Luengo-Fernández et al.2 However, this again highlights the
conservative approach taken in our modelling.
In terms of opportunity cost, any programme that reduces the
rate of death from cardiovascular disease by 1% is cost effective
up to costs of £30m, as long as no alternative programme causes
a bigger reduction at the same costs or the same reduction at
lower costs. Varying the underlying Framingham risk equation
to include newer values such as QRISK2 will also be useful.
39
However, the resulting changes are likely to be small.
Furthermore, subsequent research should ensure that such
models remain up to date, accessible, and credible. A better
quantification of our understanding of causal pathways for
cardiovascular disease will be challenging but important.
An important factor is the feasibility of population-wide dietary
changes—for instance, in salt consumption. Cultural aspects
are important in some countries, such as salted fish in Portugal
and salted vodka further east. However, most populations now
live in a global economy. We eat what is available, affordable,
and acceptable. In our UK study population, that means that
more than 80% of consumed salt is concealed in processed
food.22 35 In the UK, media campaigns and voluntary agreements
with the food industry have already achieved a 1 g reduction in
salt consumption. We therefore suggest that a 3 g reduction
might be entirely feasible by using more muscular regulatory
approaches. The 6 g reductions in Finland and Japan were
achieved in spite of cultural traditions and resistance from the
industry.22 29 Furthermore, reductions of 5-10% in the salt content
of any specific food during one year are simply not noticed by
most consumers. This is because human taste buds adapt very
quickly. Salt has already been substantially decreased in the UK
and several other countries, with no evidence of widespread
compensation by consumers.35
This paper does not detail the specific costs of particular
programmes. It is making a more general argument. Given the
benefits in terms of increased health and reduced healthcare
costs, the sorts of programmes we have seen work in other
countries must surely also be cost effective here.
Conclusions
Our model is relatively simple and transparent with clear
limitations. However, the cumulative conservative assumptions
mean that the benefits and cost savings are almost certainly
underestimated. The findings are reassuringly consistent with
results from very different methods in the United States,
Australia, and the UK Treasury.7-9 26 27 40 Population-wide
prevention interventions seem to be both powerful and cost
saving.
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Tables
Table 1| Discounted outcomes for intervention achieving given relative risk reduction sustained over 10 years
Annual equivalent
savings (£m)Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)
Relative risk
reduction
3261070.320.001
1513249371.7120.005
3126598743.5250.01
625301971497.0500.02
9379629522410750.03
1231063394299141000.04
1541330493374181250.05
1861597592449211500.06
2171865692524251750.07
2482133791600282010.08
2792402891675322260.09
3102671990751352510.1
467402414921132533780.15
626538919971516715070.2
786676625071903896370.25
9478155302122941087680.3
11109557354026891269000.35
127510 9714062308814510330.4
144012 3974589349016411680.45
160713 8365121389518313040.5
QALY=quality adjusted life year.
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Table 2| Discounted outcomes for intervention with given percentage reduction in systolic blood pressure sustained over 10 years
Annual equivalent
savings (£m)Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)
Percentage reduction in
systolic blood pressure
108633241.180.5
2017365482.2161
3026098723.3241.5
40347131964.4322
504351641215.5402.5
615221971456.7483
716102301697.8573.5
816992631948.9654
9178729621910.0734.5
10287633024311.2815
QALY=quality adjusted life year.
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Table 3| Discounted outcomes for intervention with given percentage reduction in cholesterol concentration sustained over 10 years
Annual equivalent
savings (£m)Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)
Percentage reduction
in cholesterol
86826190.960.5
1613651381.7131
2420577572.6191.5
32274103763.5252
40343129954.4322.5
484121551145.3383
564811811346.1453.5
645512081537.0514
726212341727.9584.5
806912601928.8645
QALY=quality adjusted life year.
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Table 4| Discounted estimates of total population effects from reduction of 3 g/day in salt intake sustained over 10 years, by age and sex
Annual equivalent
savings (£m)Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)Age groups (years)
Men:
54721120.514.440-49
65321160.714.950-59
64917150.744.860-69
328870.453.170-79
Women:
64819110.394.040-49
54618130.513.850-59
54516140.643.960-69
4311090.483.270-79
40347131964.4332.2Totals
Any apparent anomalies with addition are due to rounding effects.
QALY=quality adjusted life year.
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Table 5| Discounted estimates of total population effects from intervention based on legislation against trans fats sustained over 10 years,
by age and sex
Annual equivalent
savings (£m)Total savings (£m)
QALYs gained
(×1000)
Life years gained
(×1000)
Deaths prevented
(×1000)
Cases prevented
(×1000)Age groups (years)
Men:
28243107642.72340-49
37322129964.33050-59
393351191005.13360-69
2320057513.32370-79
Women:
2723492531.91940-49
2823994682.72050-59
3026195823.72360-69
2319961583.12170-79
235203375457126.8191Totals
QALY=quality adjusted life year.
Any apparent anomalies with addition are due to rounding effects.
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